BioMediTech at the University of Tampere (UTA) is part of the joint BioMediTech institute of the UTA and Tampere University of Technology (TUT).
BioMediTech is a joint institute of the University of Tampere (UTA) and Tampere University of Technology (TUT). Its research activities cover diverse areas, including cell and molecular biology, genetics, biomaterials, biosensors, computational systems, biotechnology, biomedical engineering, and regenerative medicine.
At BioMediTech, UTA and TUT educate together top-level experts with multidisciplinary skills in life sciences for the demands of both academia and industry. The students apply to and their studies are administered by either UTA or TUT.
These pages concentrate on the BioMediTech activities administered by the University of Tampere. The issues concerning the joint institute can be found on the institute's webpages.
A new, vast international study backs up the theory of PALB2 gene as a clinically significant predisposition to breast cancer in addition to the already known risk genes BRCA1 and BRCA2. The research shows that women with rare PALB2 gene mutation have approximately 35 % risk of getting breast cancer by the age 70. The research is useful especially for genetic counselling: a gene test can be taken into clinical use, and the women carrying the PALB2 mutation can be directed to closer follow up for breast cancer.